Biogen 3Q Revenues: $3.1 billion (+4%) 3Q Earnings: $1.2 billion (+19%) YTD Revenues: $9.0 billion (+5%)    YTD Earnings: $2.8 billion (-7%) Comments: Multiple sclerosis revenues, including approximately $65 million in royalties on the sales of OCREVUS, were $2.3 billion in the quarter. TECFIDERA sales were $1.1 billion in the quarter, up 3%. Total Interferon sales were $662 million, down 7%. AVONEX sales were also down 7% to $538 million. TYSABRI revenues were $469 million, down 9%. PLEGRI...